We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Puretech Health Plc | LSE:PRTC | London | Ordinary Share | GB00BY2Z0H74 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 3.20 | 1.89% | 172.20 | 748,334 | 16:29:57 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 172.20 | 173.80 | 174.60 | 165.80 | 165.80 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Home Health Care Services | USD 65.12M | USD -65.7M | USD -0.2744 | -6.28 | 404.62M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:37:32 | AT | 100 | 172.20 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 05/11/2024 | 12:05 | UK RNS | PureTech Health PLC PRTC's Seaport Adds Biotech Finance Exec as CFO |
| 01/11/2024 | 07:00 | UK RNS | PureTech Health PLC Total Voting Rights |
| 31/10/2024 | 17:00 | UK RNS | PureTech Health PLC Director/PDMR Shareholding |
| 30/10/2024 | 11:00 | UK RNS | PureTech Health PLC PRTC to Present at UBS and Jefferies Conferences |
| 21/10/2024 | 06:00 | UK RNS | PureTech Health PLC PRTC's Seaport Closes $225M Series B Financing |
| 09/10/2024 | 09:03 | ALNC |  PureTech Health investigates IPF disease burden amid treatment testing |
| 09/10/2024 | 06:00 | UK RNS | PureTech Health PLC PRTC's IPF Patient Research & Ph 2b On Track YE24 |
| 01/10/2024 | 11:00 | UK RNS | PureTech Health PLC PRTC to Give 3 Presentations at CHEST 2024 Meeting |
| 27/9/2024 | 10:30 | ALNC | PureTech Health celebrates KarXT approval by FDA for schizophrenia |
| 27/9/2024 | 06:00 | UK RNS | PureTech Health PLC KarXT/Cobenfy Approved by FDA; PRTC Receives $29M |
Puretech Health (PRTC) Share Charts1 Year Puretech Health Chart |
|
1 Month Puretech Health Chart |
Intraday Puretech Health Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 12/11/2024 | 14:54 | PureTech Health - innovative healthcare | 2,553 |
| 22/7/2018 | 20:35 | PureTech Health (PRTC) One to Watch Monday | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-11-12 16:37:32 | 172.20 | 100 | 172.20 | AT |
| 2024-11-12 16:35:16 | 172.20 | 108,156 | 186,244.63 | UT |
| 2024-11-12 16:29:57 | 172.20 | 52 | 89.54 | AT |
| 2024-11-12 16:28:16 | 173.45 | 1,400 | 2,428.27 | O |
| 2024-11-12 16:26:26 | 173.80 | 774 | 1,345.21 | O |
| Top Posts |
|---|
Posted at 12/11/2024 08:20 by Puretech Health Daily Update Puretech Health Plc is listed in the Home Health Care Services sector of the London Stock Exchange with ticker PRTC. The last closing price for Puretech Health was 169p.Puretech Health currently has 239,421,312 shares in issue. The market capitalisation of Puretech Health is £412,283,499. Puretech Health has a price to earnings ratio (PE ratio) of -6.28. This morning PRTC shares opened at 165.80p |
Posted at 30/10/2024 14:07 by takeiteasy Seaport announcements a master stroke in my book i.e. ensure a well over subscribed funding round and then follow up to the IIs with the message if you want more of the Seaport exposure without having to wait for the next funding round then buy some/more PRTC ... and heh presto PRTC price shoots up ..lols...:)nai etc |
Posted at 06/10/2024 05:50 by takeiteasy PureTech is currently evaluating two doses of LYT-100, one with comparable exposure to the approved dose of pirfenidone and one with a higher level of exposure, in a global, randomized double blind, placebo-controlled trial in patients with IPF, which is expected to serve as the first of two registration enabling trials. As previously noted, the Company has taken measures to accelerate enrollment. Phase 2B results are now expected in 4Q24.Liberum see a successful outcome adding £320m / £1.25 per share to the target price (TP). Oakbloke review of PRTC - August 2024 |
Posted at 06/10/2024 03:54 by ohisay Liberum in their figurings late last year had LYT100 unrisked at 380m$.If my maths is correct that works out at £1.20p per share to PRTC . Given that theres nothing much in the current share price for that atm, one might reasonably expect an extra £1 per share in a success case. They say .. Depending on the outcome of the ELEVATE IPF Phase IIb trial, we believe that LYT-100 has >$1bn sales potential and LYT-100 would be attractive to a potential licensing partner, whether that be a company looking to enter the field or an existing player like Roche, who might see LYT-100 as an attractive means to extend its market position with a new potential backbone therapy |
Posted at 25/9/2024 06:53 by takeiteasy Bristol-Myers Squibb: Hold Rating Justified by Market-Reflected Approval of KarXT Despite Promising Clinical DataTipRanks Sep. 23, 2024, 05:15 AM BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $48.00. Evan Seigerman has given his Hold rating due to a combination of factors, notably the anticipation that KarXT’s approval is already reflected in the current market price of Bristol-Myers Squibb’s shares. He acknowledges that while the approval of KarXT is expected given its strong clinical data, the actual impact on the stock will depend on the specifics of the drug’s label and the company’s ability to execute a successful launch. Seigerman also points out that a label without the black box warning typically associated with antipsychotics could provide a slight upside, but that this potential benefit appears to be accounted for in the stock’s valuation. hxxps://markets.busi So chaps, does our share price already reflect approval for Karxt? |
Posted at 06/9/2024 07:20 by return_of_the_apeman Indeed fantastic news and it opened downI would like the cash coming from the first milestone payment to be deployed, for example as another buyback to support the share price and so we all get a bigger share of what is going to be a very rewarding company one day The price will be under cash on the books come the expected milestone payment? and although a predator would have to pay a premium they could buy the majority of this up using Purtech's own cash if the board are not careful |
Posted at 26/7/2024 06:55 by takeiteasy Tbf the share price has been royally punished and BOD have missed out on just about all of the Russell2000/biotech mini boom over the past few weeks. So hopefully they realise their mea culpa and the price us as shareholders pay for their mistakes :) |
Posted at 25/7/2024 07:40 by ashkv At 167p - a market cap of GBP 400.64 million per Google Finance or at GBPUSD 1.29 Market Cap is US$516.8 million in dollar terms!!Net Cash of PRTC is US$ 473.3 million or nearly 92% of market cap (US$ 473.3mn/ US$516.8mn) equivalent to 153.2p!!! PRTC doesn't have any debt!!! NO VALUE TO UPCOMING ROYALTY STREAM OF US$400 million, other investments or drugs in development!!! GREAT TIME TO ANNOUNCE FURHTER BUYBACKS!!! Share price down nearly 1/3 since recent 250p tender offer!!! Nearly 50% upside at present levels to 250p recently concluded tender offer!!! |
Posted at 03/7/2024 14:17 by bahiflyer I'm amazed Invesco still have so many left. They've been drip feeding them down for the last 3 years or so it seems. Rather than buy backs, which did nothing for the share price last time, PRTC should open a dialogue with Invesco to find out what holding they'd be happy to stop selling at and either buy off them direct or find an alternative II to have an interest. That would be much easier to instigate if there was an actual dividend policy, which is after all the only long term way of returning money to shareholders directly, and that's what income funds want, which in turn would stimulate overall share price growth. It's something a decent PR team or advisers would point out to them |
Posted at 26/6/2024 12:20 by ashkv At 186p (156p (Cash Component)/188p) = 84% of share price is net cash / PRTC has no debtNo value for sizeable assets / Karuna residual payments etc Sitting duck!!! |
Posted at 21/3/2024 10:33 by wassapper So please help me here. The tender offer will be at 250p per share (if it proceeds)?Current share price is 222p So if I buy more now (to add to my goodly amount), sometime in April/May, I'll be offered 250p a share for some of my shares by the company? Do I make an "instant" 28p per share or just for a proportion? If so why aren't more share being bought? What happends to the share price after the tender offer (all things being equal)? Does it drop like a typical ex-divi action? First time tender for me so quite confused. I am sure many of these questions will be asked again! Thanks! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
